Translating JAKs to Jakinibs

Gadina, M., Chisolm, D. A., Philips, R. L., McInnes, I. B. , Changelian, P. S. and O'Shea, J. J. (2020) Translating JAKs to Jakinibs. Journal of Immunology, 204(8), pp. 2011-2020. (doi: 10.4049/jimmunol.1901477) (PMID:32253269)

Full text not currently available from Enlighten.

Abstract

The discovery of JAKs and STATs and their roles in cytokine and IFN action represented a significant basic advance and a new paradigm in cell signaling. This was quickly followed by discoveries pointing to their essential functions, including identification of mutations as a cause of SCID. This and other findings predicted the use of therapeutically targeting JAKs as a new strategy for treating immune and inflammatory diseases. This now is a reality with seven approved jakinibs being used to treat multiple forms of arthritis, inflammatory bowel disease and myeloproliferative neoplasms, and numerous ongoing clinical trials in other settings. This story provides interesting insights into the process of translating basic discoveries and also reveals the need to return to basic work to fill gaps that now become apparent.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain
Authors: Gadina, M., Chisolm, D. A., Philips, R. L., McInnes, I. B., Changelian, P. S., and O'Shea, J. J.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Research Centre:College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology
Journal Name:Journal of Immunology
Publisher:American Association of Immunologists
ISSN:0022-1767
ISSN (Online):1550-6606

University Staff: Request a correction | Enlighten Editors: Update this record